Dr. Siddharth Sheth, MD
Claim this profileUNC Lineberger Comprehensive Cancer Center
Studies Skin Cancer
Studies Squamous Cell Carcinoma
5 reported clinical trials
13 drugs studied
Area of expertise
1Skin Cancer
Stage IV
HPV negative
HPV positive
2Squamous Cell Carcinoma
Stage IV
PD-L1 positive
HPV negative
Affiliated Hospitals
Clinical Trials Siddharth Sheth, MD is currently running
Immunotherapy +/− Targeted Therapy
for Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Recruiting1 award Phase 2
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting2 awards Phase 316 criteria
More about Siddharth Sheth, MD
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Siddharth Sheth, MD has experience with
- Pembrolizumab
- Cetuximab
- Durvalumab
- Intensity Modulated Radiotherapy Treatments
- Cisplatin
- External Beam Radiotherapy
Breakdown of trials Siddharth Sheth, MD has run
Skin Cancer
Squamous Cell Carcinoma
Oral Cancers
Head and Neck Squamous Cell Carcinoma
Throat Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Siddharth Sheth, MD specialize in?
Siddharth Sheth, MD focuses on Skin Cancer and Squamous Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are HPV negative.
Is Siddharth Sheth, MD currently recruiting for clinical trials?
Yes, Siddharth Sheth, MD is currently recruiting for 3 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Siddharth Sheth, MD has studied deeply?
Yes, Siddharth Sheth, MD has studied treatments such as Pembrolizumab, Cetuximab, Durvalumab.
What is the best way to schedule an appointment with Siddharth Sheth, MD?
Apply for one of the trials that Siddharth Sheth, MD is conducting.
What is the office address of Siddharth Sheth, MD?
The office of Siddharth Sheth, MD is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.